$12.48
▲ +0.6% Today
as of Sep 4, 16:56 ET
Last 30 days
Recent Press Releases & News
Zevra Therapeutics to Present at Upcoming Investor Conferences
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Overview
52-week range
$7.16
$15
68% of range
Avg surprise (last 3)
+101.6%
Avg reaction (last 2)
+3.8%
100% positive
Latest IV / EM
53%
EM ±8.2% · $12 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $0.14 | — | — | — | — | financials |
| Wed May 6, 2026 | Mar/2026 | $0.18 | $0.06 | +200.0% | +400.0% | +6.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.01 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.06 | $-0.09 | +33.3% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.06 | $-0.21 | +71.4% | — | +1.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.69 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.48 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $40M | $36M | — | $26M | $26M | $20M | — | $4M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $17M | $52M | — | $4M | $-71M | $-5M | — | $-27M |
| Net income | $9M | $38M | — | $-544,000 | $75M | $-3M | — | $-33M |
| EPS (diluted) | $0.14 | $0.60 | — | $-0.01 | $1.21 | $-0.06 | — | $-0.69 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $145M | $96M | $62M | $54M | $48M | $37M | $34M | $54M |
| Inventory | $2M | $2M | $2M | $1M | $1M | $3M | $2M | — |
| Total current assets | $251M | $230M | $223M | $225M | $226M | $82M | $86M | $99M |
| Total assets | $303M | $279M | $285M | $270M | $256M | $173M | $178M | $192M |
| Long-term debt | $0 | $0 | $62M | $61M | $61M | $60M | $60M | $59M |
| Total liabilities | $85M | $73M | $130M | $137M | $139M | $132M | $138M | $122M |
| Total equity | $218M | $206M | $155M | $133M | $117M | $41M | $40M | $70M |